Fosamprenavir Expanded Access
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00240552 |
Recruitment Status
:
Completed
First Posted
: October 18, 2005
Last Update Posted
: September 12, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infection, Human Immunodeficiency Virus | Drug: fosamprenavir Drug: Telzir® | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 85 participants |
Official Title: | An Open-label Phase III Study to Provide Access to Fosamprenavir and to Assess the Long Term Safety and Tolerability of Fosamprenavir Containing Regimens in HIV Infected Patients With Limited Treatment Options |
Study Start Date : | July 2003 |
Actual Study Completion Date : | August 2005 |

-
Drug: fosamprenavir
Drug: Telzir®

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 infected subjects.
-
Subjects must belong to one of the following populations:
- Subjects with limited treatment options due to viral resistance, interactions, or tolerability issues with other antiretroviral drugs.
- Subjects who already receive amprenavir (Agenerase®)
- Subjects for whom once daily dosing of antiretroviral therapy is indicated, including, once daily dosing with fosamprenavir/ritonavir.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240552
Switzerland | |
GSK Investigational Site | |
Aarau, Switzerland, 5001 | |
GSK Investigational Site | |
Basel, Switzerland, 4031 | |
GSK Investigational Site | |
Bern, Switzerland, 3010 | |
GSK Investigational Site | |
Bruderholz, Switzerland, 4101 | |
GSK Investigational Site | |
La Chaux-de-Fonds, Switzerland, CH 2301 | |
GSK Investigational Site | |
Lausanne, Switzerland, 1011 | |
GSK Investigational Site | |
Lugano, Switzerland, 6900 | |
GSK Investigational Site | |
Luzern, Switzerland, 6000 | |
GSK Investigational Site | |
St Gallen, Switzerland, 9007 | |
GSK Investigational Site | |
Zurich, Switzerland, 8008 | |
GSK Investigational Site | |
Zurich, Switzerland, 8038 | |
GSK Investigational Site | |
Zurich, Switzerland, 8091 |
Study Director: | GSK Clinical Trials | ViiV Healthcare |
Responsible Party: | ViiV Healthcare |
ClinicalTrials.gov Identifier: | NCT00240552 History of Changes |
Other Study ID Numbers: |
APV40005 |
First Posted: | October 18, 2005 Key Record Dates |
Last Update Posted: | September 12, 2016 |
Last Verified: | September 2016 |
Keywords provided by ViiV Healthcare:
protease inhibitor Treatment Experienced amprenavir fosamprenavir |
GW433908 HIV pro drug |
Additional relevant MeSH terms:
Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Slow Virus Diseases Fosamprenavir HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |